Nanobiotix (NASDAQ:NBTX) Hits New 52-Week High – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) hit a new 52-week high on Tuesday . The stock traded as high as $30.35 and last traded at $30.31, with a volume of 175540 shares traded. The stock had previously closed at $23.60.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Friday, September 19th. Leerink Partners set a $14.00 target price on Nanobiotix in a research report on Thursday, September 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $11.00.

Nanobiotix Trading Up 28.4%

The business has a fifty day moving average price of $12.56 and a 200 day moving average price of $7.21.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.